AA: Method of Measuring Comorbidity to Predict Outcome After Intensive Care

Sponsor
Uppsala University (Other)
Overall Status
Completed
CT.gov ID
NCT04109001
Collaborator
(none)
223,495
131.9

Study Details

Study Description

Brief Summary

In this study the investigators will validate the impact of comorbidity on readmission to intensive care unit (ICU) and mortality after ICU and which method of measuring comorbidity that is most predictive.

The study population included all critical care patients' registries in Swedish intensive care registry (SIR) during the years 2005 to 2012 with valid personal identity number. Data from Statistics Sweden och National Board of Health and Welfare were linked to data from SIR and de-identified.

Hospital discharge diagnoses from five year preceding the index date for the ICU admission were extracted. A composite outcome of death and readmission will be analyzed.

Analyzes with cox proportional-hazards regression, time to event, on the training data set year 2005-2010 The study population will be split in a training data set (2005-10) and a test data set (2011-12) for validating our prognostic model. The predictive ability in the test data set were evaluated based on discrimination, AUC (C index), Calibration and Brier score.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In this study the investigators will validate the impact of comorbidity on readmission to intensive care unit (ICU) and mortality after ICU and which method of measuring comorbidity and in which time-point it is most predictive.

    The study population includes all critical care patients' registries in Swedish intensive care registry (SIR) during the years 2005 to 2012 with valid personal identity number. SIR delivers the population to Statistics Sweden directly or via the client for further delivery to Statistics Sweden. For all individuals in the population, data are collected from registers at Statistics Sweden. Statistics Sweden supplies social security numbers and serial numbers to the National Board of Health for further data collection there. The National Board of Health and Welfare delivers the data sample to the client who sends it to Statistics Sweden for collaboration and anonymous. All data material is stored unidentified in the MONA database where only persons connected to the project have access to the material.

    The data set containing 293 342 observations and 223 495 unique individuals. Observations which is totally covered in time by another observation are excluded. Two consecutive observations with less than 24 hours between them consider as the same visit. The final set of dates consists of 273 741 observations (223 495 individuals).

    Patients with recurrent ICU stays during the study period were considered as recurrent events that are not independent of each other. The interval between ICU discharge and readmission was used both as an outcome variable and to characterize the patient at the time to admission. In the analyzes the dependency between multiple admissions for the same individual was handled using a robust sandwich estimator. Every ICU stay was included in the study but handled as a time-updated exposure.

    A composite outcome of death and readmission will be analyzed. Death and readmission will also be analyzed separately. Follow-up starts at admission. A binary status variable (no/yes) is created reflecting if the outcome has happened or not together with a corresponding time variable. For each admission the follow-up ends with readmission, death or end of study (2016-12-31) whichever comes first.

    Hospital discharge diagnoses from five years preceding the index date for the ICU admission were extracted from the National Board of Health and Welfare and linked to the SIR data using exact person-based linkage. The Charlson comorbidity index was calculated based on this information. A different categorization of comorbidity was also performed as modified based from the categorization proposed by Elixhauser. For each of 36 defined comorbidity categories the number of admissions with a primary diagnosis, the number of admissions with a secondary diagnosis, the total length of stay with a primary diagnosis, and the interval from the last admission with the comorbidity condition as a primary diagnosis, were calculated.

    The underlying condition causing ICU admission was categorized according to diagnosis and admitting department.

    Analyzes with cox proportional-hazards regression, time to event, on the training data set year 2005-2010 Charlson comorbidity index (CCI) categorical 0, 1, 2, 3-5, 6-9, 10-17 Elixhauser 36 categories

    1. Number of primary diagnosis (count)

    2. Number of secondary diagnosis (count)

    3. Total care time primary diagnosis (count)

    4. Time interval from latest primary diagnosis (missing, count)

    Analyzes

    A Age + sex B A + CCI C A + a D A + a + b E A + a + b + c F A + a + b + c + d

    There was by definition no missing data in the comorbidity variables. Missing information concerning age and sex were minimal and did not require imputation. The proportional hazards assumption was checked using the Kaplan-Meier Curves.

    The study population will be split in a training data set (2005-10) and a test data set (2011-12) for validating our prognostic model. The predictive ability in the test data set were evaluated based on discrimination, area under curve (AUC) (C index), Calibration and Brier score.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    223495 participants
    Observational Model:
    Cohort
    Time Perspective:
    Other
    Official Title:
    Method of Measuring Comorbidity and Time-point to Predict Readmission and Mortality of Intensive Care Patients: an Observational Study Using Linked Data From National Registers of Hospital Care and Cause of Death
    Actual Study Start Date :
    Jan 1, 2005
    Actual Primary Completion Date :
    Dec 31, 2015
    Actual Study Completion Date :
    Dec 31, 2015

    Outcome Measures

    Primary Outcome Measures

    1. The ability of comorbidity to predict death after intensive care [For each admission the follow-up ends with readmission, death or end of study (2016-12-31) whichever comes first.]

      A composite outcome of death and readmission will be analyzed. Death and readmission will also be analyzed separately. Follow-up starts at admission. A binary status variable (no/yes) is created reflecting if the outcome has happened or not together with a corresponding time variable.

    2. The ability of comorbidity to predict readmission after intensive care [For each admission the follow-up ends with readmission, death or end of study (2016-12-31) whichever comes first.]

      A composite outcome of death and readmission will be analyzed. Death and readmission will also be analyzed separately. Follow-up starts at admission. A binary status variable (no/yes) is created reflecting if the outcome has happened or not together with a corresponding time variable.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All critical care patients' registries in SIR during the years 2005 to 2012

    • Valid personal identity number

    Exclusion Criteria:
    • Age 16 and older

    • No valid personal identity number

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Uppsala University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Uppsala University
    ClinicalTrials.gov Identifier:
    NCT04109001
    Other Study ID Numbers:
    • Anna Aronsson
    First Posted:
    Sep 30, 2019
    Last Update Posted:
    Jan 10, 2020
    Last Verified:
    Jan 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jan 10, 2020